BKA
ENTA icon

Brick & Kyle Associates’s Enanta Pharmaceuticals ENTA Stock Holding History

Brick & Kyle Associates’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-3,725
Closed -$109K – 432
2016
Q1 		$109K Hold
3,725
– – 0.09% 119
2015
Q4 		$123K Sell
3,725
-200
-5% -$6.52K 0.11% 107
2015
Q3 		$142K Hold
3,925
– – 0.13% 106
2015
Q2 		$177K Hold
3,925
– – 0.15% 97
2015
Q1 		$120K Sell
3,925
-900
-19% -$35K 0.1% 122
2014
Q4 		$245K Buy
+4,825
New +$216K 0.21% 83

Other funds holding ENTA

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Brick & Kyle Associates's ENTA Position: Q2 2016 in Review

Brick & Kyle Associates sold out of Enanta Pharmaceuticals (ENTA) in Q2 2016, closing a stake of 3,725 shares — an estimated $109K sold.

Brick & Kyle Associates first reported a position in ENTA in Q4 2014 and held it in 6 quarters. The position peaked at $245K in Q4 2014. 129 funds tracked by Wall St. Rank hold ENTA as of Q2 2016.

  • Brick & Kyle Associates reported no remaining Enanta Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Brick & Kyle Associates sold 3,725 Enanta Pharmaceuticals shares in Q2 2016, an estimated $109K.
  • Brick & Kyle Associates first reported a position in Enanta Pharmaceuticals in Q4 2014 and held it in 6 quarters.
  • Brick & Kyle Associates's Enanta Pharmaceuticals position peaked at $245K in Q4 2014.
  • 129 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2016.

Based on Brick & Kyle Associates's 13F filing for Q2 2016, filed 5 Aug 2016.